TransMedics Group Inc vs Venture Global Inc. Class A common stock — how do they compare? TransMedics Group Inc trades at $79.33 (market cap $2.81B), while Venture Global Inc. Class A common stock trades at $13.27 (market cap $32.63B). The key difference: Venture Global Inc. Class A common stock is far larger — about 11.6× TransMedics Group Inc's market cap, and Venture Global Inc. Class A common stock pays a 1.23% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Venture Global Inc. Class A common stock for 0 Days on average.
| TMDX | VG | |
|---|---|---|
Market Cap | $2.81B | $32.63B |
Volume | 962,415 | 11,874,428 |
Sector | Health | Energy |
52-Week High | $150.42 | $17.53 |
52-Week Low | $61.99 | $5.92 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $3.21B | $72.01B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →Venture Global develops, builds, and operates liquefied natural gas export facilities. Its projects connect U.S. natural gas supply with global LNG markets.
Read more on VG →